⬅ # 385 Jung-jin Seo|# 387 Magdalena Martullo-Blocher

# 386 Zhu Yi 


Real Time Net Worth
as of 7/12/2024
-$234.5M (-3.32%)

# 386 Zhu Yi 


Real Time Net Worth
as of 7/12/2024
-$234.5M (-3.32%)
Source of WealthPharmaceuticals
ResidenceChengdu, China
Age-Adjusted Net Worth$7.07B
Zhu Yi
Zhu Yi
Net worth: $7.07B

Self-Made Score 



Zhu Yi is the chairman and CEO of Biokin Pharmaceutical, renowned for its development of anesthesia injections, cancer drugs, and traditional Chinese medicine treatments.
Biokin's IPO in Shanghai in January 2023 raised $136 million, catapulting Zhu into billionaire status.

Early Life and Education

Zhu Yi began his career as an educator, teaching immunology and microbiology at West China Medical University.
His academic background laid the foundation for his later ventures in pharmaceuticals.

Founding Biokin Pharmaceuticals

In 1996, Zhu Yi founded Biokin Pharmaceuticals, a modern bio-pharmaceutical company integrating R&D, manufacturing, and marketing of chemical drugs and biologics.
The company's diverse product range includes children's medicine, cardiovascular drugs, anesthetics, and chronic disease drugs.

Expansion and Subsidiaries

Biokin's subsidiary, Systlmmune, based in Redmond, Washington, specializes in cancer drug development.
The company operates globally, conducting businesses in multiple countries.

How long would it take you to become as rich as Zhu Yi?

If you started with $10,000 and invested an additional $500 each month at a 44.15% CAGR, it would take you 5 years to reach Zhu Yi's net worth of $7.07B.

Is this realistic? It depends how closely the VIX-TA-Macro Advanced model performs to its history in the future. Since Grizzly Bulls launched on January 1, 2022, it's returned 51.86% compared to 19.03% for the S&P 500 benchmark.

Enter data in all but one field below, then calculate the missing value

Zhu Yi is very wealthy, but what's stopping you from reaching that same level of success? As summarized in our five fundamental rules to wealth building, becoming wealthy in a modern capitalist economy is not complicated. There's actually only three variables:

  1. Your starting capital
  2. Your earnings after expenses
  3. The compound annual growth rate (CAGR) of your savings

Most people start with zero or very little, so if you weren't born into wealth, don't fret! The majority of the fortunate folks listed in our Grizzly Bulls’ Billionaires Index came from middle class or lower backgrounds. The most distinguishing characteristic of the group is their ability to consistently earn a high CAGR on their savings.

Every billionaire has a unique strategy to achieve high CAGR. For Zhu Yi, Pharmaceuticals is the primary source. Whether you choose to invest your savings in your own businesses or the businesses of others is not as important. The salient piece of the puzzle is ensuring that your hard-earned savings are generating sufficient CAGR to reach your long term goals.

Most people simply invest their money in index funds and call it a day. There's nothing wrong with this approach, but it guarantees relative mediocrity. To achieve greatness, you need to invest your money to earn higher than average returns. In the long run, better investors will always finish ahead of better earners.

Source: Grizzly Bulls reporting

Methodology: Grizzly Bulls' Billionaires Index is a daily ranking of the world's billionaires and richest people. Grizzly Bulls strives to provide the most accurate net worth calculations available. We pull data from public equity markets, SEC filings, public real estate records, and other reputable sources.

The index is dynamic and updates daily at the close of U.S. stock market trading based on changes in the markets, economy, and updates to Grizzly Bulls' proprietary algorithm of personal wealth calculation. Stakes in public companies are tracked daily based on the relevant closing prices of the underlying securities. Additionally, stakes in private companies, cash, real estate, and other less easily valued assets are updated periodically through careful analysis of insider transactions, comparable public company sales / EBITDA multiples, etc.

Edited by: Lee Bailey